A novel steroid-eluting active fixation lead significantly reduced chronic atrial pacing thresholds at 1 year compared to a conventional lead (0.20 vs 0.54 μC; P<0.01).
Absolute Event Rate: 0.2% vs 0.54%
p-value: p=<0.01
A new lead design was tested that combined a small microporous steroid‐eluting electrode with an insulated, exposed helix for active fixation. This lead (model 5078, Medtronic, Inc., group I. n = 10) was compared to a conventional model (model Y 60 BP, Biotronik) with a larger surface of polished platinum‐iridium, equipped with a fixed, noninsulated screw but without steroid elution (group II, n = 10). The two lead models were studied in the atrial position of dual chamber pacing systems, which all had a tined ventricular lead (model 5024, Medtronic, Inc.), with essentially the same steroid‐aluting tip as the new active fixation lead design. Sensing and pacing data were recorded acutely and during 1 year of follow‐up, via the telemetry of a Relay pulse generator (Intermedics. Inc.). Intraoperatively, unfiltered atrial electrogram amplitudes did not differ between groups (group I; 7.12 ± 2.56 mV vs group II: 6.42 ± 1.87 mV; P > 0.05), nor did sensing thresholds 1 year after implantation (group I: 5.33 ± 1.70 mV vs group II: 4.26 ± 1.40 mV; P > 0.05). Atrial pacing thresholds as measured during surgery at a pulse width of 0.5 msec were lower in group I (0.49 ± 0.15 V) than in group II (0.68 ± 0.19 V; P < 0.05). From day 5 through day 360 of follow‐up, the difference in atrial pacing thresholds was highly significant (P < 0.01). with a smaller peaking of early thresholds and a much lower scattering of data for the steroid screw‐in leads than for controls. Chronic thresholds as measured 1 year postimplant in terms of minimum charge delivered for capture were 0.20 ± 0.03 μC in group I versus 0.54 ± 0.11 μC in group II (P < 0.01). There was no difference between groups on the ventricular level, both acutely and during follow‐up. If the active fixation atrial lead was compared to its tined ventricular counterpart in group I, pacing thresholds only differed within the early days postimplant, but they were virtually identical from week 3 through 1 year. It is concluded that the novel pacing lead design effectively combines low energy pacing with more versatility in electrode positioning by use of the active fixation mechanism.
Fröhlig et al. (Wed,) conducted a other in Patients requiring dual chamber pacing systems (n=20). Steroid-eluting active fixation lead (model 5078) vs. Conventional non-steroid-eluting active fixation lead (model Y 60 BP) was evaluated on Chronic atrial pacing thresholds (minimum charge delivered for capture) at 1 year (p=<0.01). A novel steroid-eluting active fixation lead significantly reduced chronic atrial pacing thresholds at 1 year compared to a conventional lead (0.20 vs 0.54 μC; P<0.01).